Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen ESA Sales Dive In The Biotech’s “Toughest” Year

Executive Summary

Sales of Amgen's Aranesp and Epogen took a hit in the fourth quarter as the safety of erythropoiesis-stimulating agents was questioned, Amgen reported during its fourth quarter and year-end earnings call Jan. 24. Going into 2008, the company will develop a risk management plan and other strategies to help address the situation
Advertisement

Related Content

CMS Begins National Coverage Determination Process For ESAs In The Renal Setting
As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
Amgen’s Bundling Of ESAs With Neulasta and Neupogen Draws House Scrutiny
Drug Safety Concerns Help Depress U.S. Sales Forecasts From IMS Health
The Year Ahead: Bisphosphonate Class Faces Generic Competition – Fosamax Goes Off Patent
CMS issues revised ESA reimbursement instructions
Amgen, J&J Revise Labels For Aranesp, Epogen, Procrit
Aranesp Bad Luck Catches Up To Amgen, Forces Pharma-Style Reorganization
Advertisement
UsernamePublicRestriction

Register

PS049222

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel